Compare Danaher Corporation (DHR) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares MSCI Singapore ETF — how do they compare? Danaher Corporation trades at $219.99 (market cap $152.87B), while iShares MSCI Singapore ETF trades at $31.57 (market cap $1.49B). The key difference: Danaher Corporation is far larger — about 102.6× iShares MSCI Singapore ETF's market cap, and Danaher Corporation pays a 0.74% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares MSCI Singapore ETF for 45 Days on average.
| DHR | EWS | |
|---|---|---|
Market Cap | $152.87B | $1.49B |
Volume | 5,228,698 | 2,142,305 |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $34.57 |
52-Week Low | $161.91 | $26.71 |
Typical Hold Time | 69 Days | 45 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
EWS, the iShares MSCI Singapore ETF, trades at $32.48, down 2.17% amid bearish technical signals. The ETF recently hit a 52-week high, driven by Singapore's economic strength and AI momentum, but faces selling pressure with key support at $32. Financial ratios are unavailable, limiting fundamental clarity.
Outlook remains mixed; Singapore's growth and institutional interest offer upside, but stretched valuations and technical weakness pose risks. Investors should weigh regional economic resilience against potential pullbacks in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
